Defining a set of standardised outcome measures for newly diagnosed
patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Precious Cat Litter co-founder Kathy Elsey was
diagnosed with multiple myeloma in 2009, and she and her husband Bruce have supported the efforts of the MMRF ever since.
«Lenalidomide maintenance following autologous stem cell transplant can now be considered a standard of care for
people with multiple myeloma,» says Dr. McCarthy, senior author on the meta - analysis and Principal Investigator of the U.S. study, CALGB (Alliance) 100104.
Geraldine Ferraro, the first woman to run for vice president on a major party ticket and a congresswoman who championed Queens in the House for six years, died Saturday in Boston after a 12 - year
battle with multiple myeloma, a blood cancer.
«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients
with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.
«A cancer therapy that targets TP53 would not be as effective for African -
Americans with multiple myeloma as it would be for a white population because doctors would be trying to fix the wrong mutated gene,» said Manojlovic, assistant professor of research translational genomics at the Keck School of Medicine.
Winston died at his home in Malibu surrounded by family after a seven - year
struggle with multiple myeloma, according to a representative from Stan Winston Studio.
Precious Cat Litter has teamed up
with the Multiple Myeloma Research Foundation (MMRF) for its #CatsAgainstCancer campaign, which aims to raise awareness and find a cure for multiple myeloma, a rare form of blood cancer.
It is the most common type of amyloidosis in the United States, with estimates of up to 2000 cases diagnosed each year, and occasionally
occurs with multiple myeloma.
At the time his death, on May 18, 2012, he was penning the autobiographical Close to the Bone, a book about his fifteen + year
relationship with multiple myeloma (bone cancer), the treatments that followed, and the effects the disease and modern medicine had upon his life and spiritual beliefs.
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients
with multiple myeloma awaiting autologous haematopoietic stem cell transplantation?
Researchers have designed a nanoparticle - based therapy that is effective in treating
mice with multiple myeloma, a cancer of immune cells in the bone marrow.
Empliciti will be used in combination with two other drugs to treat patients
with multiple myeloma who have received one to three prior courses of medication.
In 1995, Etkin's first wife, Susan, was diagnosed
with multiple myeloma.
The indication now covers patients with bone metastases from solid tumors and
those with multiple myeloma.
«Despite new therapies, it's virtually inevitable that a patient
with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
With multiple myeloma, most patients live four to seven years from their date of diagnosis, and most become resistant to chemotherapy drugs over time.
They turned them into fat cells and cultured the fat cells
with multiple myeloma.
Researchers at Washington University School of Medicine in St. Louis have developed a nanotherapy that is effective in treating mice
with multiple myeloma, a cancer of bone marrow immune cells.
When injected into mice
with multiple myeloma, the targeted nanoparticles carrying the Myc inhibitor increased survival to 52 days compared with 29 days for mice receiving nanoparticles not carrying the drug.
While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients
with multiple myeloma, there have been no definitive results regarding overall survival.
A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated
with multiple myeloma and a condition that occurs in approximately one - fourth of very aggressive multiple myeloma, extramedullary disease or EMD.
«Lenalidomide maintenance therapy improves overall survival for patients
with multiple myeloma.»
Tse and the team analyzed the degree of expression of AF1q in 117 patients
with multiple myeloma.
«Minimal Residual Disease Status, Outcomes in Patients
with Multiple Myeloma.»
Patients
with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.
Even though patients
with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one - time flu shot does not offer adequate immune response.
«Effect of follow - up of MGUS on survival in patients
with multiple myeloma.»
In this specific study, among other studies the group has published in this area, mice
with multiple myeloma — a malignant disease of the plasma cells produced in bone marrow and spread throughout the body via the circulatory system — were treated with the selective anti-cancer drug Velcade (bortezomib).
The method also is being evaluated in a clinical trial involving patients
with multiple myeloma.
«Therapy shrinks tumors in patients
with multiple myeloma.»
Pilar de la Puente, PhD (left), and Kareem Azab, PhD, of Washington University School of Medicine in St. Louis, have developed a screening tool that may predict quickly and more accurately the best treatments for individual patients
with multiple myeloma.
«And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients
with multiple myeloma.»
The FDA approved elotuzumab (Empliciti) for patients
with multiple myeloma.
For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients
with multiple myeloma.
We have one of the most comprehensive CAR T cell programs in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials in the coming year, including for patients
with multiple myeloma, prostate cancer, liver cancer and breast cancer.